ArticleThe European respiratory journal2026
Large-scale proteomic profiling identifies distinct inflammatory phenotypes in acute respiratory distress syndrome: a multicentre, prospective cohort study.
Article in The European respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Early differential protein expression in blood and bronchoalveolar fluid among ARDS phenotypes.Scientific reports · 2026Trial
- The Acute Respiratory Distress Syndrome (ARDS): epidemiology, etiology, molecular mechanisms, diagnosis and therapeutic strategies.Molecular biomedicine · 2026Review
- Review
- Stress-hyperglycemia ratio and glycemic variability predict severity and mortality in sepsis-associated acute respiratory distress syndrome.World journal of emergency medicine · 2026Article
- Computed tomography in ARDS, from morphological insights to AI-powered multi-modal analysis: a narrative review.Journal of intensive care · 2026Review
- Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome.Medical sciences (Basel, Switzerland) · 2026Review
- A proteomics and redox proteomics approach to understanding ARDS heterogeneity.Scientific reports · 2026Article
- Splenic PD-L1Research (Washington, D.C.) · 2026Article
- Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential.Frontiers in microbiology · 2026Review
Corrections and comments
- Commented on by
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHost responses during acute respiratory distress syndrome are highly heterogeneous, contributing to inconsistent therapeutic outcomes. Proteome-based phenotyping may identify biologically and clinically distinct phenotypes to guide precision therapy.
methodsIn this multicentre cohort study, we used latent class analysis of targeted serum proteomics to identify acute respiratory distress syndrome phenotypes. Serum samples were collected within 72 h of diagnosis to capture early-phase profiles. Validation was conducted in external cohorts. Pathway enrichment assessed molecular heterogeneity. Lung computed tomography scans were analysed using machine learning-based radiomics to explore phenotypic distinctions. Heterogeneous treatment effects for glucocorticoids and ventilation strategies were evaluated using inverse probability of treatment weighting adjusted Cox regression. A multinomial XGBoost model was developed to classify phenotypes.
resultsAmong 1048 patients, three inflammatory phenotypes (C1, C2, C3) were identified and validated in two independent cohorts. The phenotype C1, with a larger proportion of poorly/non-inflated lung compartments, had the highest 90-day mortality and shock incidence and fewest ventilator-free days, followed by C3, while C2 patients had the best outcomes (p<0.001). Phenotype C1 was characterised by intense innate immune activation, cytokine amplification and metabolic reprogramming. Phenotype C2 demonstrated immune suppression, enhanced tissue repair and restoration of anti-inflammatory metabolism. Phenotype C3, comprising the oldest patients, reflected an intermediate state with moderate immune activation and partial immune resolution. Glucocorticoid therapy and higher positive end-expiratory pressure ventilation improved 90-day outcomes in C1 but increased mortality in C2 patients (p
conclusionsWe identified and validated three proteome-based acute respiratory distress syndrome phenotypes with distinct clinical, radiographic and molecular profiles. Their differential treatment responses highlight the potential of biomarker-driven strategies for acute respiratory distress syndrome precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.